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index date for the comparator group was randomly chosen to reduce selection bias. 
A 1-year continuous health plan enrollment was required before and after the index 
date for both groups. Study outcomes, including health care costs and utilizations, 
were compared between the disease and comparator groups using 1:1 propensity 
score matching (PSM). Results: Eligible patients (N= 384,596) were identified for 
the prostate cancer and comparison cohorts and after applying PSM, a total of 
112,693 patients were matched from each group and the baseline characteristics 
were well-balanced. Patients diagnosed with prostate cancer were more likely to be 
hospitalized (75.41% vs. 2.46%, p< 0.01), and report more emergency room (9.30% vs. 
5.45%, p< 0.01), outpatient (99.77% vs. 61.15%, p< 0.01) and pharmacy visits (85.65% 
vs. 63.77%, p< 0.01). Patients diagnosed with prostate cancer also incurred higher 
costs for inpatient ($2,216 vs. $695, p< 0.01), emergency room ($92 vs. $51, p< 0.01), 
outpatient ($3,364 vs. $1,462, p< 0.01), pharmacy ($582 vs. $413, p< 0.01) and total 
costs (6,162 vs. $2,571, p< 0.01) compared to the comparator group. ConClusions: 
Patients diagnosed with prostate cancer were associated with a higher burden of 
illness compared to their matched controls during a period of 12 months.
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objeCtives: Everolimus and axitinib are approved to treat patients with metastatic 
renal cell carcinoma (mRCC) following failure on various first-line therapies. This 
analysis assessed the cost of care with everolimus versus axitinib for second-line 
mRCC patients from a Canadian payer perspective. Methods: Costs considered 
in this analysis included those related to drug acquisition and adverse events (AEs). 
Drug acquisition costs were based on the Ontario wholesaler price. Adverse event 
costs were based on the Ontario Case Costing Initiative and literature. Drug costs, 
adjusted for dose intensity, and AE costs, based on daily incidence rates, accrued 
for the duration of treatment in each arm; the sums of these costs were compared 
across treatments. The mean dose intensities, treatment durations and rates of 
AEs in the treatment arms were the calculated from trial data. Scenario analyses 
are presented to estimate the range of costs within the treatment arms. Costs are 
presented in 2011 Canadian dollars. Results: In the base case analysis, the total 
cost of treatment with everolimus was estimated to be $24,931 while the total cost 
of treatment with axitinib was $39,010. The primary driver of the cost discrepancy 
was axitinib’s high dose intensity, resulting in high drug acquisition costs. Despite 
analysis limitations, the trend of the results remained consistent across scenario 
analyses. When treatment duration was estimated from median progression-free 
survival estimates in each study’s post-sunitinib populations, the total cost of treat-
ment with everolimus was $8,339 less than with axitinib. Sensitivity analyses that 
assumed equivalent treatment durations between each arm also demonstrated 
lower overall treatment costs for everolimus patients. ConClusions: The analysis 
demonstrates that everolimus provides a less costly treatment option than axitinib 
for patients requiring second-line therapy. Significant uncertainty remains regard-
ing axitinib’s treatment duration and dosing, which could result in higher costs to 
the health care system compared to everolimus.
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objeCtives: Ipilumumab is a clinically proven treatment option for pre-treated 
metastatic melanoma (MM). Ipilumumab has clearly demonstrated survival ben-
efit, that is prolonged in a proportion of the responding patients. Karweit J and 
colleagues (2012) demonstrated that mean overall survival (OS) can be particularly 
useful for agents with a right-skewed survival curve where a subset of patients 
respond to treatment with long term survival. The research has demonstrated that 
several agents, including ipilimumab for MM, bevacizumab for non-small cell lung 
cancer, sorafenib for hepatocellular carcinoma, lenalidomide for multiple mye-
loma and trastuzumab for metastatic breast cancer (among others) have shown 
greater mean OS improvement than median OS improvement, reflecting the long 
term survival benefit for some patients. In this analysis we select oncologic agents 
that have demonstrated mean OS benefit in the above mentioned study and have 
received license in Mexico. We compare the relative economic value delivered by 
each asset, which broadly represent the therapeutic oncologic class. Methods: 
The economic value of the analogues is estimated for the Mexican private per-
spective in terms of cost per month of mean OS versus comparators. The analy-
sis relies on the cost to treat to mean progression by the months of mean OS 
improvement. Results: Cost per month of OS for ipilimumab ($15,993 USD) when 
compared to bevacizumab, sorafenib, trastuzumab, sunitinib, lenalidomide and 
vemurafenib is below the average relative cost of the assets (range from $35,871 
to $9,845 USD). ConClusions: This study demonstrates that ipilimumab is a 
competitive asset in terms of value for money. The analysis allows to evaluate 
within a clear and robust analytical framework, the reimbursement decisions 
across the oncologic therapeutic class in Mexico.
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objeCtives: To measure the costs of two pilot interventions within the National 
Institutes of Health-funded Centers for Population Health and Health Disparities 
(CPHHD) designed to improve health outcomes in medically underserved commu-
estimates do not count multiple episodes of the same event. Costs of managing 
each adverse event were obtained from the literature and averaged across west-
ern European countries (UK, Germany, France, Italy, Belgium, Spain, Sweden, and 
Switzerland), where available. The costs were inflated to 2012 Euros (€ ). Results: 
Expected per-patient costs of managing adverse events within the first year of treat-
ment among patients with advanced breast cancer receiving EVE+EXE were € 730. 
Among patients receiving capecitabine, docetaxel, or doxorubicin as single-agent 
chemotherapy, expected per-patient costs were € 1721, € 2390, and € 1230, respectively. 
The most costly adverse event for patients treated with EVE+EXE was anemia (€ 152 
per patient). The most costly adverse event for patients treated with capecitabine, 
docetaxel, or doxorubicin was lymphocytopenia (€ 861 per patient), neutropenia 
(€ 821 per patient), and leukopenia (€ 382 per patient), respectively. ConClusions: 
Expected costs of managing adverse events in patients with HR+/HER2- advanced 
breast cancer receiving EVE+EXE are about one-half to one-third of the costs for 
those receiving chemotherapies. This economic consideration can have important 
implications for health care spending in the advanced breast cancer setting.
PCN57
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objeCtives: To estimate the economic impact of managing chemotherapy patients 
at risk of neutropenia and eligible to receive Granulocyte-Colony Stimulating Factor 
(G-CSF) with lipegfilgatrim (LONQUEX, a new long-acting G-CSF) rather than peg-
filgastrim in Spain. Methods: Both the BIA and CMA were conducted from the 
Spanish-payer’s perspective: they included direct drug cost, administration, neutro-
penic events and adverse event costs, but did not consider indirect costs. The drug 
acquisition cost of lipegfilgatrim used in the model was based on the anticipated 
price of lipegfilgatrim at the time of launch in Spain. All costs were expressed in 
EUROS-2013. A range of sensitivity, scenario and threshold analyses were performed. 
An additional analysis was performed within the BIA to explore the trend towards 
fewer dose modifications in the lipegfilgatrim arm of the XM22-03 trial. Results: 
The CMA shows that treating a patient with lipegfilgatrim instead of pegfilgrastim 
resulted in a cost saving of 650,06€ . At the population level, the BIA predicts that 
cost savings could range from 113.166€ in year 1 to 678.995€ in year 5, totaling to 
2.489.648€ over five years. Furthermore, the BIA shows a potential to avoid 50 dose 
modifications with the use of lipegfilgatrim instead of pegfilgrastim. The model is 
most sensitive to the cost of pegfilgrastim and lipegfilgatrim, but results are robust, 
with the model estimating cost savings over a wide range of inputs. When the trend 
towards decreased NE and increased AE with lipegfilgatrim vs pegfilgrastim reported 
in the XM22-03 trial is explored, cost savings was about 30% compared to the default 
scenario, reaching 3.208.619 € ., mainly due to decreased NE costs ConClusions: 
Lipegfilgatrim is cost-saving compared with pegfilgrastim. These savings are con-
firmed across a wide range of input values.
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objeCtives: There are relatively few treatment options for pre-treated metastatic 
melanoma (MM) patients. Clinicians have recently been provided access to a new 
option, ipilumumab that has demonstrated long-term survival benefits, in a subset 
of patients. Karweit J and colleagues (2012) present data to support the use of mean 
OS for agents with a right-skewed survival curve, where a subset of patients respond 
to treatment with long term survival -as is the case for ipilimumab. The research 
presents data for several oncology agents: ipilimumab for MM, bevacizumab for non-
small cell lung cancer, sorafenib for hepatocellular carcinoma, lenalidomide for mul-
tiple myeloma, trastuzumab for metastatic breast cancer and vemurafenib for MM. 
The data reveals a greater mean OS improvement than median OS improvement, 
since mean OS accurately captures the complete survival benefits. In this analysis 
we select agents from the Krweit J et al study and who have received regulatory 
authorization in Colombia, to compare their relative economic value. Methods: 
The economic value of each asset is presented in terms of cost per month of mean 
OS within the Colombian health care payer perspective. The analysis uses the cost 
to treat to mean progression of each asset divided by the months of mean overall 
survival improvement using current list prices of assets. Results: Ipilimumab in 
comparison to bevacizumab, sorafenib, trastuzumab, sutinib, lenalidomide, and 
vemurafenib demonstrates a clinical and economic relative value. The cost per mean 
overall survival month gained for ipilumumab ($39,344,362 COP) is below the average 
of the comparator assets (range from $60,226,690 to $20,166,226). ConClusions: 
The relative clinical and economic value of ipilumumab in the context of a variety 
of oncologic assets is clearly documented. This data provides health care decision 
makers critical data when determining coverage of oncologic treatments.
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objeCtives: To examine the economic burden and health care utilizations of pros-
tate cancer patients in the U.S. veteran population. Methods: Patients diagnosed 
with prostate cancer (ICD-9: 185.xx) were identified from the U.S. Veterans Health 
Administration (VHA) Medical SAS dataset from October 1, 2009 through September 
30, 2011. The first diagnosis date was defined as the index date. A comparator group 
was created by identifying patients without prostate cancer but with the same age, 
region, gender, index year, and matched baseline Charlson Comorbidity Index. The 
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objeCtives: To assess the management and associated lifetime costs in MM patients 
as from the diagnosis of unresectable metastatic disease until death. Methods: A 
retrospective patient chart review was performed at the Antwerp University Hospital 
to obtain data on medical consumption related to the management of unresectable 
MM (uMM). A complete registry of all melanoma patients who visited the hospi-
tal between 2007 and May 2013 was compiled. Eligible for this retrospective chart 
review were patients with uMM with sufficient data available and who deceased 
before May 2013. Data on demographics, disease characteristics and management 
of uMM were collected. Direct costs were calculated by multiplying each item of 
resource use with its unit cost (2013, € ) using the Belgian public health care payer’s 
perspective (PHCP) and patient’s perspective. Average (bootstrap 95%CI) overall costs 
per patient were calculated. Results: Out of 338 registered melanoma patients, 
35 were eligible and included in this chart review. The median overall survival time 
(OS) in all patients was 6.2 months. 88.6% (n= 31) of patients were treated by sys-
temic treatment(s) of which 17% (n= 6) received up to 4 different treatment lines. 
Ten patients received “new drugs”: ipilimumab (1 to 4 cycles): 10; vemurafenib: 2. 
Fifty-six (41%) of the 137 hospitalizations were for treatment administration. The 
mean overall cost per patient was € 43,429 (bootstrap 95% CI: 33,372 - 54,351), of 
which € 42,367 (95%CI: 32,481 - 52,976) was reimbursed. The PHCP cost was driven 
by systemic treatments costs (46% of cost). Mean PHCP cost was € 87,468 (95 % CI: 
77,372-97,307) for patients treated with “new drugs” versus € 24,327 (95 % CI: 18,617 - 
30,634) for patients not treated with “new drugs”. Median OS was 9 and 4.9 months, 
respectively. ConClusions: Management of uMM results in considerable costs for 
the PHCP, mainly driven by systemic treatment costs.
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objeCtives: Few recent data are available on breast cancer treatment costs, espe-
cially by stage of the disease at diagnosis. This study was designed to estimate the 
management costs in breast cancer for the first 5-year period following diagno-
sis. Costs have been distinguished by stage of severity. Methods: A patient-level 
analysis was performed from a French physician survey database, collecting data 
on patient demographics, cancer history from diagnosis and treatment patterns. 
Data were extracted for all breast cancer cases with at least 1 year of follow-up after 
diagnosis using data collected from 2011 to 2012. Cost analyses were conducted 
from a health care payers’ perspective adjusting for stage (stages I-IV) at diagnosis 
and year from diagnosis. Results: A total of 1,157 patients were included in the 
analysis. The stages at diagnosis distribution was respectively from stage I to IV 
29.7%, 39.2%, 15.0% and 16.1%. The mean (SD) age at inclusion was 62.5 (12.4) and 
the mean (SD) time from diagnosis was 5.0 years (5.1). The mean annual cost (SD) 
over the 5-year period after diagnosis was ranging from 4,293€ (9,526€ ) for stage I 
to 12,111€ (19,070€ ) for stage IV. The mean (SD) annual costs for the 1st year after 
diagnosis were estimated at 11,647€ (9,883€ ), 13,226€ (11,575€ ), 17,254€ (14,535€ ) 
and 24,003€ (24,888€ ), respectively for stage I to IV at diagnosis. The main cost con-
tributors in early stages were radiotherapy and surgery while cytotoxic treatments, 
hormonotherapy and supportive care droved it for the late stage. The mean annual 
costs for the following years after diagnosis (2nd to 5thyear) decreased, ranging from 
1,827€ (8,964€ ) for Stage I to 5,370€ (10,662€ ) for stage IV. ConClusions: : The mean 
annual cost was strongly related to the clinical stage at diagnosis and the year from 
diagnosis. These estimates could be useful to populate models that explore impact 
of treating and preventing breast cancer.
PCN67
the humaNistiC aNd eCoNomiC burdeN of veNous thromboembolism 
iN CaNCer PatieNts: a systematiC review
Kourlaba G.1, Relakis J.2, Kontodimas S.3, Holm M.V.4, Maniadakis N.2
1National and Kapodistrian University of Athens School of Medicine, Athens, Greece, 2National 
School of Public Health, Athens, Greece, 3LEO Pharmaceutical Hellas S.A., Athens, Greece, 4LEO 
PHARMA, Copenhagen Area, Denmark
objeCtives: To systematically review the humanistic and economic burden of 
cancer-related venous thromboembolism (VTE). Methods: A literature search 
was carried out on Pubmed, Cochrane Central Register of Controlled Trials, Econlit, 
Science Direct, JSTOR, Oxford Journals and Cambridge Journals. The search was 
limited to humanistic studies published from January 2000 to December 2012. 
Additional studies were also identified by searching reference lists of relevant 
published reviews and included studies. The identified studies were indepen-
dently reviewed by two reviewers against pre-determined inclusion and exclu-
sion criteria. A quality assessment of the selected studies was also conducted by 
using standard methods . The data of selected studies were extracted onto a data 
extraction form and consequently synthesized. Results: Fifty five studies were 
included in our review. It was found that cancer patients experience between 
2-fold and 20-fold higher risk of developing VTE in comparison to non-cancer 
patients. Cancer patients are more likely to experience a VTE event in the first 3 
or 6 months after cancer diagnosis and the onset of chemotherapy. Additionally, 
an increased risk of VTE in patients with distant metastases and certain types of 
cancer (i.e. pancreatic or lung) was identified. VTE strongly affects the prognosis 
of cancer patients as it has been found that it is a leading cause of death in this 
group of patients. The annual average total cost for cancer patients with VTE was 
found to be almost 50% higher compared to that of cancer patients without VTE 
nities through the utilization of allied health professionals. Methods: Two local 
CPHHD programs with prospective randomized controlled trial designs (a virtual 
team care intervention aimed at reducing depressive symptoms in older adults 
with depression and cardio-metabolic syndrome, and a patient navigator program 
to increase mammography screening for breast cancer) provided the underlying 
data for this analysis. The programs collected detailed resource use data along 
with several clinical measures. Costs were measured from a payer perspective. 
The navigator program involved in-person or remote navigator consultations, and 
costs were based on a wage rate of $15 per hour. The depression program involved 
multiple services and all costs reflected institution-specific billing data. Results: 
There were 949 patients in the patient navigator intervention. On average, these 
patients received 8.28 minutes of navigator services per patient over the phone and 
1.23 minutes via in-person visits, translating to a per-patient cost of $2.38. For the 
six patients enrolled in the team care intervention for depression, resources used 
included social worker case management and individual psychotherapy, translating 
to program costs of $145 per patient over 12 months. Spillover health care service 
costs were similar between the intervention and control groups (intervention = 
$55 per patient, control = $64 per patient). ConClusions: Costs are an important 
consideration for evaluating pilot, team-care based interventions to improve patient 
health. The two programs evaluated here offer insight into the potential impact of 
interventions that employ allied health professionals and demonstrate a relatively 
low cost per patient. Future work will examine these costs in comparison with 
measured effects of the program.
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objeCtives: To investigate the self-reported burden imposed by care of lung 
cancer (LC) patients in the European Union (EU). Methods: The study included 
respondents to the 2010 and 2011 EU National Health and Wellness Survey from 
France, Germany, Italy, Spain, and the UK who reported being caregivers for a rela-
tive with LC versus respondents who did not report being caregivers for a relative 
with any condition (control). Outcome measures included Short Form (SF)-6D 
health state utilities and mental and physical health status (all derived from the 
SF-12v2), stress-related comorbidities, health care resource use during the past 
6 months, and work/activity impairment during the past week using the Work 
Productivity and Activity Impairment (WPAI) questionnaire. Productivity losses 
were converted into costs using the human capital method by applying median 
hourly wages per country (from Eurostat 2006 personal income inflated to 2010) 
to the total number of hours lost using results from WPAI. Multivariable analyses 
were used to test the potential impact of LC patient caregiving on health care 
resource use and work/activity impairment, as well as costs specifically associated 
with work impairment. Results: A total of 107 caregivers for patients with LC and 
103,868 non-caregivers were identified. Compared with non-caregivers and adjust-
ing for covariates, caregivers had higher mean levels of impaired presenteeism 
(27.1% vs. 14.8%), overall work impairment (32.4% vs. 18.0%), and activity impair-
ment (32.8% vs. 21.8%; all p< 0.005); higher odds of impact across all measures 
of the WPAI including absenteeism (all p< 0.01); and higher annual costs associ-
ated with impaired presenteeism (€ 5,672 vs. € 3,429) and overall work impairment 
(€ 6,905 vs. € 4,147; both p< 0.05). Health care resource utilization and mean level 
of absenteeism did not differ significantly. ConClusions: LC patient caregiving 
in the EU is associated with significantly higher work/activity impairment and 
related costs relative to non-caregivers. Costs associated with LC caregiver burden 
deserve further attention.
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objeCtives: To determine direct medical costs of treating patients with Chronic 
Lymphoid Leukemia (CLL) from the Brazilian Public Healthcare System perspec-
tive. Methods: A retrospective longitudinal analysis of the Government admin-
istrative claims database (Datasus) was performed. Eligibility criteria were patients 
starting CLL (ICD-10 code C911) chemotherapy from Jan/2008 to Dec/2011, with 
complete information and no inconsistency in date of birth, gender. Outpatient 
and inpatient databases were combined through deterministic linkage. Outcome 
was direct medical costs (DMC), calculated as the sum of the medical claims for 
each patient included in the analysis, for a maximum period of 5 years or death or 
loss of follow-up, whichever comes first. DMC was categorized in chemotherapy, 
hospitalizations, and other outpatient costs. Results: From 5100 patients with CLL 
identified in the database, 613 met eligibility criteria. Median follow-up time was 25 
months. This population cohort had 54% males with average age at start of treat-
ment of 66.4 ± 11.7 years. Patients received an average of 12.0 ± 9.4 months of chemo-
therapy treatment, with 71% of them treated by one type of chemotherapy regimen. 
Total DMC in this population was R$ 7,021,631.48 (average cost of R$ 6,404.52 ± 
6,133.37 per patient-year), from which R$ 5,384,552.12 (77%) are related to chemo-
therapy, R$ 1,062,978.98 (15%) to hospitalizations and R$ 574,100.38 (8%) to other 
outpatient costs. Outpatient laboratory exams accounted for 6% (R$ 397,050.07) of 
total DMC. 30 (5%) patients underwent radiotherapy treatment, with total costs of 
R$ 53,944.96 (< 1% of DMC). A total of 862 hospitalizations were identified in 287 
(46.8%) patients, with an average cost of R$ 1,233.15 ± 3,879.86 per hospitaliza-
tion. ConClusions: Patients with CLL represent a significant economic burden 
to the public health system. Chemotherapy and hospitalization costs accounts for 
more than 90% of the total costs.
